FibroBiologics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
6.66M
on 2026-07-31, from 1.64M on 2024-05-14 10-Q ↗
Earlier counts are adjusted for the 1-for-20 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
$7.5M
Agreement of 2026-05-01. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
12.01M
Warrants of every class as tagged in the XBRL facts on 2026-06-30, exercise price $1.44. 10-Q ↗
Cash
1 quarters
$3.5M on 2026-06-30 ÷ $3.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-09-15 | Private placement | 298,508 | $1.675 | $500K | 8-K ↗ |
| 2026-06-25 | Private placement | 4,081,633 | $0.735 | $3.0M | 8-K ↗ |
| 2026-04-01 | Public offering incl. 1.24M pre-funded, with warrants at $1.32 | 2,272,728 | $1.32 | $3.0M | 424B4 ↗ |
| 2026-03-31 | Private placement incl. 1.24M pre-funded | 2,487,880 | not read | $3.0M | 8-K ↗ |
| 2025-12-14 | Public offering with warrants at $0.33 | 5,227,275 | $0.33 | $1.7M | 424B5 ↗ |
| 2025-12-14 | Registered direct offering | 5,227,275 | not read | $1.7M | 8-K ↗ |
| 2025-11-24 | Public offering with warrants at $0.34 | 4,477,614 | $0.335 | $1.5M | 424B5 ↗ |
| 2025-11-24 | Registered direct offering | 4,477,614 | not read | $1.5M | 8-K ↗ |
| 2025-11-19 | Public offering incl. 8.57M pre-funded, with warrants at $0.33 | 12,110,203 | $0.3303 | not read | 424B5 ↗ |
| 2025-11-18 | Registered direct offering incl. 8.57M pre-funded | 17,140,406 | not read | $4.0M | 8-K ↗ |
Also on file: a 1-for-20 reverse split, 2026-03-30 8-K ↗